DBV Technologies
DBVT
About: DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
Employees: 109
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
300% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 4
293% more capital invested
Capital invested by funds: $16.8M [Q1] → $66.2M (+$49.4M) [Q2]
75% more funds holding
Funds holding: 16 [Q1] → 28 (+12) [Q2]
24.01% more ownership
Funds ownership: 2.4% [Q1] → 26.41% (+24.01%) [Q2]
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
|
JMP Securities
Jonathan Wolleben
|
$21
|
Market Outperform
Reiterated
|
26 Jun 2025 |
Financial journalist opinion
